ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Acute oncology hospital care at home for post-chemotherapy monitoring.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHospitalization at home (HaH) has demonstrated clinical efficacy and improved patient experience in general medicine inpatients. We conducted a quasi-experimental design study of our institution's experience with HaH among patients with multiple myeloma (MM) who received chemotherapy in the hospital and continued their hospitalization at home to complete the rest of their care.
methodsWe conducted a retrospective chart review of patients with MM who received chemotherapy with dexamethasone, cyclophosphamide, etoposide, and cisplatin with or without bortezomib (DCEP ± V) in the hospital and then continued their hospitalization at home from September 2020 to May 2023. The control cohort was all patients with MM who received DCEP ± V and lived in a zip code excluded from HaH's catchment area. Demographics, length of stay (LOS), 30-day hospital readmissions, and emergency room (ER) visits were extracted from the electronic health record. Primary endpoints were 30-day hospital readmissions and 30-day ER visits. We hypothesized that the HaH cohort was non-inferior to the control cohort.
resultsWe identified 24 HaH episodes of care and 62 in the control cohort. Patients enrolled in HaH were younger and more racially diverse. The HaH cohort had a mean total LOS, both hospital plus HaH LOS, of 16 (SD = 4.5) vs. 19.2 (SD = 11.9) days in the control (p = 0.198). Mean HaH LOS was 8.7 days (SD = 3.9), with 208.8 inpatient-bed days saved. Thirty-day hospital admissions as defined by CMS were 0% vs 1.6% in the HaH and control cohort, respectively; the 30-day ER visits had an odds ratio of 1.07 (95% CI = 0.91, 1.26), indicating non-inferiority. Successful HaH admissions occurred for 92% (95% CI = 80.6%, 100%) of care episodes.
conclusionSuccessful HaH admissions occurred for 92% of care episodes and provided significant hospital bed days saved. HaH demonstrated non-inferiority for healthcare utilization compared to standard inpatient monitoring, showcasing its potential to optimize resource utilization among this cohort of patients with MM receiving inpatient chemotherapy. These findings support the integration of HaH programs into oncology care and further studies are warranted to expand and refine HaH implementation in this population.
Indexed as
Identifiers
41866617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.